Initiating Guanfacine ER 1 mg
Start guanfacine ER at 1 mg once daily, taken at bedtime to minimize somnolence, and titrate by 1 mg weekly based on response and tolerability to a target range of 1-7 mg/day (or 0.05-0.12 mg/kg/day). 1
Dosing Algorithm
Starting Dose
- 1 mg once daily at bedtime 1, 2
- Evening administration is preferable due to the frequent occurrence of somnolence/fatigue as an adverse effect 2
- The 1 mg starting dose is appropriate whether used as monotherapy or adjunctive to stimulants 2
Titration Schedule
- Increase by 1 mg increments weekly based on clinical response and tolerability 1
- Target dose range: 1-7 mg/day or 0.05-0.12 mg/kg/day 1
- Weight-based dosing follows approximately 0.1 mg/kg as a rule of thumb 2
- Most effectiveness is achieved at 1-3 mg doses; higher doses increase adverse effects without proportional benefit 2
Critical Timing Considerations
Treatment effects are NOT immediate - expect a 2-4 week delay before observing clinical benefits 2. This differs substantially from stimulants, which have rapid onset. Set appropriate expectations with patients to prevent premature discontinuation.
Pre-Treatment Evaluation
Before initiating guanfacine, obtain:
- Personal and family cardiac history, specifically asking about:
- Sudden death in family members
- Cardiovascular symptoms
- Wolff-Parkinson-White syndrome
- Hypertrophic cardiomyopathy
- Long QT syndrome 3
- Baseline vital signs (heart rate and blood pressure) 3
- Consider ECG if cardiac risk factors are present 3
Monitoring Requirements
Cardiovascular Parameters
- Monitor heart rate and blood pressure regularly during titration and maintenance 2
- Guanfacine causes decreased heart rate and blood pressure (opposite to stimulants) 3
- Recent data show mean heart rate reduction of approximately 12 bpm without clinically significant ECG changes 4
Common Adverse Effects to Monitor
The most frequent side effects include 2:
- Somnolence (most common - can affect up to 40% of patients)
- Fatigue
- Irritability
- Headache
- Insomnia/nightmares
- Dry mouth
- Dizziness
- Abdominal pain
Approximately 80% of patients experience at least one treatment-emergent adverse event, though most are mild 5. Serious adverse events are rare 5.
Critical Safety Warnings
Discontinuation Protocol
NEVER abruptly discontinue guanfacine - always taper the dose 2, 3. While rebound hypertension is less common and delayed compared to clonidine (occurring 2-4 days post-discontinuation if it occurs), it remains a risk 6. The longer half-life of guanfacine means withdrawal effects are more gradual than with clonidine 2.
Drug Interactions
Guanfacine is primarily metabolized via CYP3A4 2. Be cautious with:
- Strong CYP3A4 inhibitors (may increase guanfacine levels)
- Strong CYP3A4 inducers (may decrease guanfacine levels)
Clinical Context
Efficacy Expectations
- Guanfacine has medium effect sizes for ADHD symptoms, generally smaller than stimulants 2
- Approximately 52-64% of patients show meaningful improvement (CGI-I score ≤2) 7, 5
- 81% continuation rate at 10 weeks in real-world adult practice 7
- Efficacy is maintained long-term with continued treatment 2
Optimal Use Cases
Consider guanfacine as first-line when:
- Stimulants are contraindicated, not tolerated, or ineffective 2
- Comorbid conditions exist: tic disorders, Tourette's syndrome, substance use disorders, or sleep disturbances 2
- "Around-the-clock" symptom control is needed (unlike stimulants with wearing-off effects) 2
- Concerns about stimulant-related appetite suppression or growth effects 2
Adjunctive Therapy
Guanfacine is FDA-approved as adjunctive therapy to stimulants 2, 3. This combination can:
- Enhance treatment effects
- Reduce stimulant-related side effects (particularly sleep disturbances, elevated blood pressure/heart rate) 2
Special Populations
Pregnancy/Breastfeeding
- Very limited safety data in pregnancy 1
- One small study (n=30) in preeclampsia showed no congenital malformations, but 20% had low birth weight 1
- No published studies on guanfacine during breastfeeding 1
- Alternative agents preferred; use only after thorough risk-benefit discussion 1